Regeneron Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Nov 29, 2022 / 04:45PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

All right. Welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team. Pleased to welcome, from Regeneron, we have Neil Stahl, Executive Vice President of R&D; John Lin, Senior Vice President of Immuno-Oncology and Head of Bispecifics Programs. From the Investor Relations group, we have Mark Hudson (inaudible) and Ryan Crowe, so thank you all for joining. A whole lot of moving parts on Regeneron, not a lot of time, but I'm hoping we can spend some time on the bispecific and ADC portfolio, high-dose EYLEA and iraE. And hopefully cover as much territory better as we can. So why don't we start on the bispecifics and the CD28 bispecifics is starting to generate a fair amount of interest.

Questions and Answers:

Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

So I guess the first question is, why start with PSMA and prostate cancer for CD28 as opposed to including
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot